Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
4.7
Journals
JoF
Special Issues
Fungal Biofilms, 2nd Edition
share announcement

Special Issue "Fungal Biofilms, 2nd Edition"

A special issue of Journal of Fungi (ISSN 2309-608X). This special issue belongs to the section "Fungal Cell Biology, Metabolism and Physiology".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1841

Special Issue Editors

Dr. Célia F. Rodrigues

E-Mail Website
Guest Editor
1H-TOXRUN - One Health Toxicology Research Unit, CESPU-IUCS, Gandra PRD, LEPABE - University of Porto, Porto, Portugal
Interests: biofilms; fungal and bacterial infections; resistance to antimicrobials; microfluidics; pathogens detection; alternative therapies; surface functionalization of biomaterials
Special Issues, Collections and Topics in MDPI journals
Dr. Lucia Černáková

E-Mail Website
Guest Editor
Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, 842 15 Bratislava, Slovakia
Interests: biofilm; Candida; MRSA; virulence; resistance; farnesol; photodynamic inactivation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Fungal infections are an important and increasing global threat, carrying not only high morbidity and mortality rates, but also high healthcare costs. Without an effective response, it is predicted that 10 million people will die per year as a result of multidrug-resistant pathogens. A high percentage of the mortalities caused by fungi are known to be biofilm-related.

This Special Issue, "Fungal Biofilms", is intended to cover the state of fungal biofilm research, from virulence and pathogenicity, to new compounds with antibiofilm and antifungal activity. We welcome reviews and original research articles covering the development/evaluation/validation of recent studies, especially those regarding multidrug resistance.

Dr. Célia F. Rodrigues
Dr. Lucia Černáková
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Fungi is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • fungi
  • infection
  • biofilm
  • Candida
  • Aspergillus
  • Cryptococcus
  • antifungal
  • resistance
  • matrix

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1447 KiB  
Article
High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms
by
Olabayo H. Ajetunmobi
,
Gina Wall
,
Bruna Vidal Bonifacio
,
Lucero A. Martinez Delgado
,
Ashok K. Chaturvedi
,
Laura K. Najvar
,
Floyd L. Wormley, Jr.
,
Hoja P. Patterson
,
Nathan P. Wiederhold
,
Thomas F. Patterson
and
Jose L. Lopez-Ribot
J. Fungi 2023, 9(9), 879; https://doi.org/10.3390/jof9090879 - 27 Aug 2023
Viewed by 826
Abstract
Candidiasis is one of the most frequent nosocomial infections affecting an increasing number of at-risk patients. Candida albicans remains the most frequent causative agent of candidiasis, but, in the last decade, C. auris has emerged as a formidable multi-drug-resistant pathogen. Both species are [...] Read more.
Candidiasis is one of the most frequent nosocomial infections affecting an increasing number of at-risk patients. Candida albicans remains the most frequent causative agent of candidiasis, but, in the last decade, C. auris has emerged as a formidable multi-drug-resistant pathogen. Both species are fully capable of forming biofilms, which contribute to resistance, increasing the urgency for new effective antifungal therapies. Repurposing existing drugs could significantly accelerate the development of novel therapies against candidiasis. Here, we have screened the Repurposing Hub library from the Broad Institute, containing over 6000 compounds, in search for inhibitors of C. albicans and C. auris biofilm formation. The primary screen identified 57 initial hits against C. albicans and 33 against C. auris. Confirmatory concentration-dependent assays were used to validate the activity of the initial hits and, at the same time, establish their anti-biofilm potency. Based on these results, ebselen, temsirolimus, and compound BAY 11-7082 emerged as the leading repositionable compounds. Subsequent experiments established their spectrum of antifungal activity against yeasts and filamentous fungi. In addition, their in vivo activity was examined in the murine models of hematogenously disseminated C. albicans and C. auris infections. Although promising, further in vitro and in vivo studies are needed to confirm their potential use for the therapy of candidiasis and possibly other fungal infections. Full article
(This article belongs to the Special Issue Fungal Biofilms, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 3605 KiB  
Review
Interactions between Bacteria and Aspergillus fumigatus in Airways: From the Mycobiome to Molecular Interactions
by
Anne Debourgogne
,
Lorra Monpierre
,
Khadeeja Adam Sy
,
Isabel Valsecchi
,
Jean-Winoc Decousser
and
Françoise Botterel
J. Fungi 2023, 9(9), 900; https://doi.org/10.3390/jof9090900 - 01 Sep 2023
Viewed by 823
Abstract
Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these [...] Read more.
Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these different microorganisms form mixed biofilms to live inside. The interactions between Gram-negative bacteria and filamentous fungi in these biofilms have attracted more attention recently. In this review, we analyse the microbiota of the respiratory tract of healthy individuals and patients with chronic respiratory disease. Additionally, we describe the regulatory mechanisms that rule the mixed biofilms of Aspergillus fumigatus and Gram-negative bacteria and the effects of this biofilm on clinical presentations. Full article
(This article belongs to the Special Issue Fungal Biofilms, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop